Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance
Pharmaceutics · 12.11.2025 · 17 (11) · 1459
DOI: 10.3390/pharmaceutics17111459 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 12.11.2025. Verfasst von Akhil Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar 144411, Punjab, India. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Tuberculosis (TB) remains a significant worldwide health challenge due to the limitations of conventional treatments and the rising incidence of drug-resistant Mycobacterium tuberculosis strains. This review consolidates the advancements in nanotechnology-based therapeutics, inhalable formulations, CRISPR–Cas tools, host-directed therapies (HDTs), and nanoparticle-based vaccine development aimed at enhancing TB management. Novel nanocarriers such as liposomes, solid-lipid nanoparticles (SLNs), dendrimers, and polymeric nanoparticles (NPs) offer enhanced bioavailability of drugs, sustained release, as well as targeted delivery to infected macrophages, thereby reducing systemic toxicity and dosing frequency. Inhalable nanomedicines provide localized delivery to the pulmonary site, enhancing the concentration of the drug at the primary site of infection. CRISPR–Cas technology is emerging as a transformative approach to disabling drug-resistant genes and enhancing diagnostic precision. HDTs, including agents like vitamin D and metformin, show potential in modulating host immune responses and enhancing pathogen clearance. Nanoparticle-based vaccines, including mRNA and antigen-conjugated platforms, aim to overcome the limitations of the BCG vaccine by enhancing antigen presentation and eliciting stronger, longer-lasting immunity. Collectively, these modalities mark a shift toward more personalized, effective, and less toxic TB therapies. However, challenges such as regulatory approval, safety, scalability, and accessibility remain. This review highlights the integrated potential of nanomedicine, gene editing, and immunomodulation to transform TB care and combat drug resistance, paving the way for more robust and durable treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar 144411, Punjab, India.
- Baba Nahar Biotech and Research, Bilaspur 174001, Himachal Pradesh, India.
- Department of Environmental Health Science, Human and Eco Care Center, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 05029, Republic of Korea.
ORCID-Profile: Akhil Sharma, Vikas Sharma, Sonu Sharma, Iyyakkannu Sivanesan
Zitieren
APA
Sharma, A., Sharma, V., Sharma, S., Sharma, S., Sharma, M., & Sivanesan, I. (2025). Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance. Pharmaceutics, 17(11), 1459. https://doi.org/10.3390/pharmaceutics17111459
Vancouver
Sharma A, Sharma V, Sharma S, Sharma S, Sharma M, Sivanesan I. Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance. Pharmaceutics. 2025;17(11):1459. doi:10.3390/pharmaceutics17111459
BibTeX
@article{Sharma2025,
author = {Sharma, Akhil and Sharma, Vikas and Sharma, Shivika and Sharma, Sonu and Sharma, Monu and Sivanesan, Iyyakkannu},
title = {Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {11},
pages = {1459},
doi = {10.3390/pharmaceutics17111459}
}
EUVIMED